|
1) National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39 (2 Suppl 1): S1-266
|
|
|
|
2) Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-100
|
|
|
|
|
3) Aldler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63: 225-32
|
|
|
|
|
|
4) Hillege HL, Fidler V, Diercks GF, et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002; 106: 1777-82
|
|
|
|
|
|
5) Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342: 145-53
|
|
|
|
|
|
6) Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease; evaluation, classification, and stratification. Ann Intern Med. 2003; 139: 137-47
|
|
|
|
|
|
7) Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-305
|
|
|
|
|
|
8) Brosius FC III, Hostetter TH, Kelepouris E, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation. 2006; 114: 1083-7
|
|
|
|
|
|
9) 平成3年度厚生省糖尿病調査研究報告書. 1991. p. 320
|
|
|
|
|
|
10) 糖尿病性腎症に関する合同委員会報告. 日腎会誌. 2002; 44: i
|
|
|
|
|
|
11) The Diabetic Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-termcomplications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-86
|
|
|
|
|
|
12) UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-53
|
|
|
|
|
|
13) Ohkubo Y, Kishikawa H, Araki E, et al: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28: 103-17
|
|
|
|
|
|
14) Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003; 348: 2285-93
|
|
|
|
|
|
15) Araki S, Haneda M, Sugimoto T, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes. 2005; 54: 2983-7
|
|
|
|
|
|
16) Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998; 339: 69-75
|
|
|
|
|
|
17) Parving HH, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int. 2006; 69: 2057-63
|
|
|
|
|
|
18) Yokoyama H, Kawai K, Kobayashi M; Japan Diabetes Clinical Data Management Study Group. Microalbuminuria is common in Japanese type 2 diabetic patients: a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDM 10). Diabetes Care. 2007; 30: 989-92
|
|
|
|
|
|
19) Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007; 30: 1577-8
|
|
|
|
|
|
20) Uzu T, Sawaguchi M, Maegawa H, et al. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care. 2007; 30: 1581-3
|
|
|
|
|
|
21) Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-9
|
|
|
|
|
|
22) 四方賢一, 槇野博史. DNETT-Japan. 医学のあゆみ. 2007; 13: 1292-5
|
|
|
|
|